JAMES POOL to Placebos
This is a "connection" page, showing publications JAMES POOL has written about Placebos.
Connection Strength
0.059
-
A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of four doses of tasosartan in patients with essential hypertension. Tasosartan Investigator's Group. Am J Hypertens. 1998 Apr; 11(4 Pt 1):454-61.
Score: 0.035
-
Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension. Am J Cardiol. 1987 May 29; 59(14):46G-50G.
Score: 0.017
-
Expanded clinical evaluation of lovastatin (EXCEL) study: design and patient characteristics of a double-blind, placebo-controlled study in patients with moderate hypercholesterolemia. Am J Cardiol. 1990 Sep 18; 66(8):44B-55B.
Score: 0.005
-
A double-blind placebo-controlled cross-over study with lidoflazine (Clinium) in post-infarction patients. Acta Med Scand. 1976; 199(1-2):17-23.
Score: 0.002